Galapagos NV (0JXZ.L)

55.22 -0.43 (-0.78%) 收市：08:01AM BST

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

版塊: 
行業: 
全職員工: 1,123

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Paulus A. Stoffels M.D., Ph.D.	CEO, Chairman, Interim Head of R&D	1.26M	無	1962
Mr. Thad Huston	Executive VP, CFO & COO	無	無	1971
Ms. Sofie Van Gijsel	Head of Investor Relations	無	無	無
Ms. Valeria Cnossen	Executive VP & General Counsel	無	無	1974
Marieke Vermeersch	Head of Corporate Communication	無	無	無
Ms. Annelies Missotten	Executive VP & Chief Human Resources Officer	無	無	1973
Ms. Ellen Van Der Aar	Head of Development	無	無	無
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D.	Senior VP & Head of Business Development	無	無	無
Mr. Dirk De Naeyer	Head of Development Operations	無	無	無
Ms. Alice Dietrich	Head of Medical Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

公司管治

截至 2024年4月1日 止，Galapagos NV 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：7；董事會：4；股東權利：4；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。